RxDoctor Payments Data

Michael Brady, DO

Family Medicine · Surprise, AZNPI 1275853715

Payments from drug & device makers

$1,713in general payments, 2019–2025

Across 51 payments — averaging $33.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$390
  • AstraZeneca$322
  • AbbVie$244
  • Medtronic$119
  • Angiodynamics, Inc.$95
  • Biotronik Inc.$77
  • plus $466 from 17 others

What the payments were for

  • Food & beverage$1,67198%
  • Education$432%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,713 in reported general payments places this provider in the 80th percentile of 2,099 family medicine providers in Arizona.

See all family medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$14,452
Medicare patients
40
Services billed
239

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide18$41,903
FarxigaDapagliflozin Propanediol13$16,203
SynjardyEmpagliflozin/Metformin Hcl11$13,724
Chlorthalidone43$1,201
Rosuvastatin Calcium51$880
Atorvastatin Calcium86$877
Pioglitazone Hcl45$812
Metoprolol Succinate23$552
Losartan Potassium44$431
Lisinopril72$390
Levothyroxine Sodium50$341
Fluticasone Propionate24$280
Tamsulosin Hcl15$208
Metformin Hcl35$204
Amlodipine Besylate41$166

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$390$41,90318 claims
AstraZenecaFarxiga$322$16,20313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,099 family medicine providers in Arizona.

Other family medicine in Surprise

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →